spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  REMICADE 

 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Jan 2021
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 May 2018
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Oct 2017
Menlo Therapeutics Expands its Management Team
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 22 Mar 2017
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
Biopharmaceuticals Endocrinology Personnel
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jun 2015
Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 14 May 2015
EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015
Biopharmaceuticals Distribution
 HSMN NewsFeed - 22 Sep 2014
Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2014
Epirus and Zalicus Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Venture Capital
 HSMN NewsFeed - 6 Jan 2014
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2013
Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 15 Apr 2013
Royalty Pharma Announces Firm Offer to Acquire Elan
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Oct 2012
BioAdvance Expands Team to Support Portfolio Companies and New Investments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 2 Jul 2012
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2012
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 26 May 2011
Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2011
Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
Biopharmaceuticals Distribution
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2010
POZEN Announces Election of Neal F. Fowler to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2008
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
In Post-Vioxx Era, Biologics Are Reviving Arthritis Treatment Market
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution
 HSMN NewsFeed - 9 Nov 2007
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
Can-Fite: CF101 May Be Effective for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 Aug 2007
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2007
Biotechnology Start-up Nuon Therapeutics Inc. Completes $5 Million Series A Financing and Names Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 4 May 2007
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 14 Nov 2006
ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Aug 2006
Kemia Closes Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Aug 2006
FDA Expands REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown to Inhibit Joint Damage and Improve Physical Function
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2006
FDA Accepts REMICADE(R) Supplemental Biologics License Application for Inhibition of Structural Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Apr 2006
FDA Grants Priority Review of REMICADE(R) for the Treatment of Children with Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Mar 2006
REMICADE(R) Is Approved in Australia for Treatment of Early Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Mar 2006
REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 6 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Jan 2006
European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
Return to NewsFeed  

 Additional items found! 64

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 64 additional stories matching:
REMICADE
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.